Aerobic exercise for Parkinson's (NCT05854524)
Aerobic exercise slows Parkinson progression
- Trial ID
- NCT05854524
- Official Title
- Exploring the Biological Basis for Exercise Neuroprotection in Parkinson's Disease
- Goal
- Aerobic exercise slows Parkinson progression
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- University of Nevada, Las Vegas
- Study Type
- INTERVENTIONAL
- Enrollment
- 90 participants
- Conditions
- Parkinson Disease
- Interventions
- Aerobic exercise
Summary For Families
Goal: to find out how moderate aerobic exercise might protect dopamine-producing brain cells in Parkinson's by triggering biological changes that support brain health. Approach: participants do 30 minutes of continuous moderate aerobic exercise with 2-3 short breaks while researchers measure blood markers and other signals, looking for increased blood flow and growth factors like BDNF, improved mitochondrial function, and reduced inflammation. The study compares people with Parkinson's to healthy adults to see which responses are disease-specific. Eligibility: adults 30 to 85, people with Parkinson's must have a neurologist diagnosis and be able to do the 30-minute exercise; anyone with major exercise risks, uncontrolled cardiovascular or respiratory issues, or dementia (MoCA 21 or below) is excluded, and controls must be generally healthy and able to exercise.
Locations
- Gait and Balance Laboratory, 217 Bigelow Health Sciences Building, UNLV, Las Vegas, Nevada, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Aerobic exercise. Goal: to find out how moderate aerobic exercise might protect dopamine-producing brain cells in Parkinson's by triggering biological changes that support brain health. Approach: participants do 30 minutes of continuous moderate aerobic exercise with 2-3 short breaks while researchers measure blood markers and other signals, looking for increased blood flow and growth factors like BDNF, improved mitochondrial function, and reduced inflammation. The study compares people with Parkinson's to healthy adults to see which responses are disease-specific. Eligibility: adults 30 to 85, people with Parkinson's must have a neurologist diagnosis and be able to do the 30-minute exercise; anyone with major exercise risks, uncontrolled cardiovascular or respiratory issues, or dementia (MoCA 21 or below) is excluded, and controls must be generally healthy and able to exercise.
- Who can participate?
- Participants must be between 30 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 9 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This is a crossover trial: instead of staying in one group, you move through a sequence of assignments, so you receive the active treatment during at least one period of the study. Ask the coordinator for the exact sequence and how long each phase lasts.